You've tried three antidepressants. Then a fourth. Your psychiatrist added an augmenting agent. You've been in therapy for months. Yet the depression persists, flattening your days and narrowing your world. Or perhaps you're a behavioral health operator watching patients cycle through medication trials, wondering if there's a more effective intervention you could offer in-house.
This is the reality of treatment-resistant depression (TRD), and it's where transcranial magnetic stimulation (TMS) enters the conversation. This complete guide to TMS therapy for treatment-resistant depression covers what patients need to know to make an informed decision and what operators need to understand before adding TMS to their program.
What TMS Actually Is and How It Works
Transcranial magnetic stimulation is a non-invasive brain stimulation technique that uses focused magnetic pulses to stimulate nerve cells in specific regions of the brain associated with mood regulation. TMS has been shown effective for treatment-resistant depression, with response defined as 50% or greater improvement on standardized depression scales.
The treatment targets the dorsolateral prefrontal cortex (DLPFC), a brain region that shows reduced activity in people with depression. During a TMS session, an electromagnetic coil placed against the scalp delivers rapid magnetic pulses that pass through the skull and generate small electrical currents in the targeted brain tissue. These currents stimulate neurons and trigger neuroplastic changes that can restore normal activity patterns.
Unlike antidepressants that circulate throughout the body, TMS acts locally on specific brain circuits. This focused approach explains why TMS produces antidepressant effects without the systemic side effects common with medications: no weight gain, no sexual dysfunction, no sedation or cognitive dulling.
The mechanism involves repeated stimulation (repetitive TMS, or rTMS) that strengthens synaptic connections and promotes the release of neurotransmitters including serotonin, norepinephrine, and dopamine. Think of it as physical therapy for underactive brain circuits.
Who Responds Best to TMS Therapy
TMS is specifically indicated for treatment-resistant depression, typically defined as inadequate response to at least two antidepressant trials of adequate dose and duration. FDA approval since 2008 covers major depressive disorder in patients not responding to antidepressants, and the evidence base has expanded significantly since then.
The strongest evidence exists for unipolar, non-psychotic major depressive disorder. Response rates are notably better in certain patient populations. Patients with shorter duration of the current depressive episode (under 5 months) and lower levels of treatment resistance show better outcomes: 43% response rate after one failed medication trial, compared to lower rates with more extensive treatment resistance.
TMS also has FDA clearance for obsessive-compulsive disorder (OCD) and is increasingly used off-label for anxious depression, generalized anxiety disorder, and PTSD. Studies in active-duty service members demonstrate TMS effectiveness even with comorbid PTSD, with completion rates around 80%.
Patient characteristics associated with better response include: first or second episode of depression (rather than chronic recurrent depression), absence of psychotic features, younger age, and concurrent engagement in psychotherapy. TMS works less reliably in patients with bipolar depression, though it can be used cautiously with mood stabilizer coverage.
The Full TMS Treatment Course: What to Expect
Understanding what a complete TMS course involves is essential for both patient decision-making and operator planning. The standard protocol consists of 30 sessions delivered 5 days per week for 6 weeks, followed by a taper phase, bringing the total to approximately 36 sessions over 6 to 9 weeks.
Each session lasts 20 to 40 minutes depending on the protocol used. You sit in a comfortable chair while a technician positions the magnetic coil against your scalp. The treatment itself involves a rapid tapping sensation and a clicking sound as the magnetic pulses are delivered. Most patients describe it as tolerable, though some find the scalp sensation uncomfortable initially.
You remain fully awake and alert throughout. There's no anesthesia, no sedation, no recovery time. You can drive yourself to and from appointments and return immediately to normal activities. This stands in sharp contrast to electroconvulsive therapy (ECT), which requires anesthesia and causes temporary cognitive effects.
Side effects are generally mild. The most common is scalp discomfort or headache during or after treatment, reported by about 30% of patients but usually resolving within the first week. Serious side effects are rare: seizure risk is approximately 1 in 30,000 treatments, lower than the seizure risk associated with many antidepressants.
Newer accelerated protocols compress treatment into days rather than weeks. Intermittent theta-burst stimulation (iTBS) delivers treatment in 3-minute sessions, and the Stanford protocol involves multiple daily sessions over 5 days. These protocols show promise but are not yet standard of care or widely covered by insurance.
Response Rates and What Happens After Treatment
Setting realistic expectations matters. Large-scale studies show approximately 46% response rate and 31% remission rate for TMS in treatment-resistant depression. Response means at least 50% reduction in depression severity; remission means symptoms have largely resolved.
These numbers mean TMS helps roughly half of patients who try it, with about one-third achieving full remission. That's clinically meaningful for a population that has already failed multiple treatments, but it also means TMS is not a universal solution. Roughly half of patients will not achieve adequate response and will need to consider other options.
Studies in veteran populations confirm these response rates, with consistent results across large samples exceeding 800 patients. This real-world data validates findings from controlled trials.
Response typically emerges gradually. Some patients notice improvement within 2 weeks, but most responders don't achieve maximum benefit until 4 to 6 weeks into treatment. This delayed response pattern is similar to antidepressants and requires patience and commitment to the full course.
Durability of response is a critical question. Studies document sustained effects up to 16 weeks following the acute treatment course. Beyond that timeframe, some patients maintain their response indefinitely, while others experience gradual symptom return.
Maintenance strategies for responders include continuation of antidepressant medication, ongoing psychotherapy, and periodic TMS "tune-up" sessions. Insurance coverage for maintenance TMS varies. Some patients return for a second full course if depression recurs months or years later, often with good results.
TMS vs. ECT vs. Ketamine for Treatment-Resistant Depression
When medications fail, patients and clinicians face a decision tree involving three primary neuromodulation options: TMS, electroconvulsive therapy (ECT), and ketamine (esketamine nasal spray or IV ketamine). Understanding how to sequence these interventions requires weighing efficacy, side effects, logistics, and patient preferences.
ECT remains the most effective treatment for severe treatment-resistant depression, with response rates of 60% to 80%. It's the gold standard for patients with psychotic depression, acute suicidality, or catatonia. However, ECT requires general anesthesia, causes temporary cognitive side effects (particularly memory impairment), and carries significant stigma. Most psychiatrists reserve ECT for patients who have failed other options or who need the most aggressive intervention.
TMS occupies a middle ground: more effective than adding another medication, less invasive than ECT. It's typically positioned after two or more failed medication trials but before ECT. The lack of cognitive side effects and anesthesia requirement makes it more acceptable to many patients. TMS is the appropriate next step for patients with moderate to severe depression who retain capacity to engage in outpatient treatment.
Ketamine offers rapid onset (often within hours to days) compared to the weeks required for TMS or ECT. Esketamine nasal spray (Spravato) is FDA-approved for TRD and must be administered in a certified healthcare setting with monitoring. IV ketamine is used off-label. Both require ongoing repeated treatments to maintain response, raising questions about long-term sustainability and cost.
The practical sequencing often looks like this: optimize medications first, add TMS if medications fail, consider ketamine for rapid stabilization or as an adjunct, reserve ECT for severe cases or multiple treatment failures. Some programs use ketamine to stabilize acute symptoms while initiating TMS for more durable response. For patients who have already explored medication options, developing a personalized treatment plan that considers all available interventions is essential.
Insurance Coverage and Prior Authorization for TMS
TMS coverage has expanded significantly since FDA approval, but navigating insurance remains complex. Most major commercial insurers now cover TMS for treatment-resistant depression, including Aetna, Cigna, UnitedHealthcare, and Blue Cross Blue Shield plans. Medicare covers TMS under specific criteria. Medicaid coverage varies by state.
Prior authorization is nearly universal and requires documentation of treatment resistance. Typical requirements include: confirmed diagnosis of major depressive disorder, failure of at least two antidepressant trials (sometimes four or more depending on the payer), current depressive episode documented by standardized scales, and absence of contraindications such as metallic implants near the treatment site.
The prior authorization process takes 1 to 3 weeks on average. Denials occur, most commonly due to insufficient documentation of prior treatment trials or failure to meet the specific definition of treatment resistance. Appeals are often successful when supported by detailed clinical documentation.
For patients without insurance coverage, out-of-pocket costs for a full TMS course range from $6,000 to $12,000 depending on geographic location and provider. Some TMS clinics offer payment plans or sliding scale fees. This cost is substantially lower than a psychiatric hospitalization but still prohibitive for many patients.
The coverage landscape continues to evolve. Accelerated protocols are generally not covered yet. Maintenance TMS coverage is inconsistent. Off-label uses (anxiety, OCD in some cases, PTSD) face higher denial rates. Operators should verify coverage before initiating treatment and build prior authorization management into their workflow.
The Operator Perspective: Adding TMS to Your Program
For behavioral health operators and psychiatrists considering TMS, the decision involves clinical, operational, and financial factors. TMS can differentiate your program, improve outcomes for your most challenging patients, and generate sustainable revenue, but implementation requires careful planning.
Equipment costs range from $60,000 for refurbished systems to $150,000 or more for new devices with advanced features. FDA clearance is required; all commercial TMS systems have this, but operators should verify. The device represents a significant capital investment with a typical useful life of 5 to 7 years and annual maintenance costs of $5,000 to $15,000.
Billing uses CPT codes 90867 (initial treatment), 90868 (subsequent treatment), and 90869 (subsequent treatment with physician evaluation). Reimbursement rates vary by payer and geography but typically range from $200 to $400 per session. With 36 sessions per patient, gross revenue per completed course is $7,200 to $14,400.
Staffing models vary. Many programs use trained technicians to deliver treatment under physician supervision, with the psychiatrist performing initial evaluations and periodic assessments. This allows one psychiatrist to oversee multiple concurrent patients. Some programs have physicians present for all treatments, which increases labor costs but may improve clinical integration.
Space requirements are modest: a private treatment room with a comfortable chair, the TMS device, and room for the operator to position the coil. Acoustic considerations matter due to the clicking sound. Most programs dedicate one room per device and can treat 6 to 8 patients per day per device.
Integration with existing services is key. TMS works best as part of comprehensive care, not as a standalone intervention. Patients need ongoing psychiatric management, often benefit from concurrent psychotherapy, and require thorough biopsychosocial assessment before starting treatment. Programs should have systems for tracking clinical outcomes using standardized measures.
The operational learning curve is real. Prior authorization management, scheduling 36 consecutive appointments, managing no-shows and treatment interruptions, and coordinating with referring psychiatrists all require refined processes. Programs considering TMS should plan for 3 to 6 months to reach operational efficiency.
Marketing and referral development matter. TMS is still unfamiliar to many patients and referring providers. Educational outreach, clear communication about appropriate candidates, and transparent discussion of response rates build sustainable referral relationships. Some programs initially struggle with patient volume, while others in underserved markets quickly develop waitlists.
For programs that also treat substance use disorders, TMS offers potential for expanded applications. While the evidence base for TMS in addiction treatment is still developing, many patients in recovery struggle with comorbid depression that may be TMS-responsive.
Who Should Not Receive TMS
Contraindications are relatively few but absolute. Patients with metallic implants in or near the head (cochlear implants, aneurysm clips, deep brain stimulators, medication pumps) cannot safely receive TMS due to risk of device malfunction or heating. Patients with a history of seizure disorder require careful evaluation, though TMS can sometimes be used with appropriate precautions.
Relative contraindications include current substance use disorders (active use may reduce treatment efficacy and increase no-show rates), unstable medical conditions, and pregnancy (not because TMS is known to be harmful, but because safety data is limited). Patients with bipolar disorder can receive TMS but require mood stabilizer coverage due to theoretical risk of inducing mania.
TMS is not appropriate for patients in acute crisis requiring higher levels of care. Patients with active suicidal planning, psychotic symptoms, or severe functional impairment typically need stabilization through hospitalization, intensive outpatient treatment, or ECT before TMS can be considered.
The Bottom Line on TMS for Treatment-Resistant Depression
TMS represents a meaningful option in the treatment algorithm for depression that hasn't responded to medications. It offers better tolerability than ECT, more durable response than ketamine for many patients, and response rates around 50% in a population that has already failed multiple treatments.
It's not a miracle cure. Half of patients won't achieve adequate response. It requires significant time commitment: 36 appointments over 6 to 9 weeks. Insurance coverage, while improving, still involves prior authorization hurdles. And even responders may need maintenance treatment or eventual retreatment.
For patients, the decision to pursue TMS should involve honest conversation with your psychiatrist about your specific situation: how many treatments you've tried, how severe your symptoms are, whether you can commit to the treatment schedule, and what your insurance covers. For many patients with treatment-resistant depression, TMS offers hope backed by solid evidence.
For operators, TMS can enhance your clinical capabilities and serve a population with significant unmet need. Success requires appropriate patient selection, operational excellence, integration with comprehensive psychiatric care, and realistic financial modeling. Programs that implement TMS thoughtfully often find it becomes a valued component of their service array.
Frequently Asked Questions
Does TMS therapy hurt?
TMS is not painful, but it's not entirely comfortable either. Most patients describe a tapping or knocking sensation on the scalp where the magnetic coil is positioned. Some people find this mildly uncomfortable, especially during the first few sessions. About 30% of patients experience headache during or after treatment, typically mild and responsive to over-the-counter pain relievers. The discomfort usually decreases as patients acclimate to treatment. You remain fully awake and alert throughout, with no anesthesia or sedation required.
How long do the benefits of TMS last?
Response durability varies by individual. Research documents sustained benefits for at least 16 weeks following the acute treatment course. Some patients maintain their response for years, while others experience gradual symptom return after several months. Factors associated with longer-lasting response include achieving full remission (not just partial response), continuing antidepressant medication and therapy, and addressing ongoing stressors. If depression returns, many patients respond well to a second TMS course. Some insurance plans cover maintenance TMS sessions (periodic treatments after the initial course) to sustain response.
What does prior authorization for TMS typically require?
Insurance prior authorization for TMS generally requires documentation of: confirmed major depressive disorder diagnosis, failure of at least two (sometimes four) antidepressant trials at adequate dose and duration, current depression severity documented with standardized scales like PHQ-9 or HAM-D, absence of contraindications, and medical necessity statement from the treating psychiatrist. The process takes 1 to 3 weeks on average. Denials most often occur due to insufficient documentation of prior treatment failures. Working with a provider experienced in TMS prior authorization significantly improves approval rates.
What are the CPT codes and reimbursement rates for TMS?
TMS billing uses CPT code 90867 for the initial treatment session, 90868 for subsequent motor threshold re-determination sessions, and 90869 for subsequent treatment sessions. Reimbursement varies by payer and region but typically ranges from $200 to $400 per session. With a standard 36-session course, total reimbursement ranges from $7,200 to $14,400. Medicare reimburses at lower rates than most commercial payers. Operators should verify rates with their specific payer mix and factor in the cost of prior authorization management, no-show rates, and equipment/staffing costs when modeling financial viability.
Should I try TMS before ketamine or ECT?
The typical treatment sequence for depression is: optimize medications first, then TMS, then ECT, with ketamine potentially fitting at various points depending on your situation. TMS is generally tried before ECT because it's less invasive, has fewer side effects (particularly cognitive effects), and doesn't require anesthesia. Ketamine offers faster onset than TMS but requires ongoing repeated treatments and has less long-term durability data. If you have severe depression with acute suicidality or psychotic features, ECT may be the appropriate first-line neuromodulation treatment. The best sequence depends on your specific symptoms, prior treatment history, and clinical urgency. This decision should be made collaboratively with a psychiatrist experienced in treatment-resistant depression.
What's the success rate for TMS in patients who have failed many medications?
Response rates decline somewhat with increasing treatment resistance. Patients who have failed one or two medication trials show response rates around 43% to 46%, while those with more extensive treatment resistance (four or more failed trials) show lower response rates, often in the 30% to 35% range. This doesn't mean TMS won't work if you've tried many medications, but it does mean realistic expectations matter. Even in highly treatment-resistant populations, roughly one-third of patients achieve meaningful benefit. Duration of the current depressive episode also matters: episodes under 5 months show better response than chronic depression lasting years.
How ForwardCare Supports TMS Program Development
Adding TMS to a behavioral health or psychiatric practice involves clinical, operational, and compliance complexity. ForwardCare helps operators evaluate and implement new service lines like TMS with the infrastructure and guidance needed for sustainable success.
From licensing support and credentialing to compliance frameworks and billing guidance, ForwardCare provides the operational backbone that allows clinical teams to focus on patient care. Whether you're exploring TMS as a potential addition to your program or working to optimize an existing TMS service, ForwardCare offers the tools and expertise to support evidence-based, financially viable program development.
If you're a patient considering TMS, talk with your psychiatrist about whether you're an appropriate candidate. If you're an operator exploring TMS for your program, reach out to discuss how ForwardCare can support your implementation process.
